Medicines Company, a drug maker for hospitals, will spend $300 million to increase its surgical product portfolio, according to Reuters.
The expenditure includes two deals, including one for $185 million to acquire Incline Therapeutics, a company developing a device to manage post-operative pain.
The other deal is for $105 million for a two-year license to market Bristol-Myers Squibb's device to control surgical bleeding.
Incline's patient-controlled analgesia system called IONSYS is for short-term management of acute post-operative pain.
More Articles on Anesthesia:
Anesthesia Machine Sales Expected to Pick Up in 2014
Heritage Valley Names Dr. Brett Anderson Chair of Anesthesiology
FDA Does Not Back Zogenix's Zohydro Pain Medication
The expenditure includes two deals, including one for $185 million to acquire Incline Therapeutics, a company developing a device to manage post-operative pain.
The other deal is for $105 million for a two-year license to market Bristol-Myers Squibb's device to control surgical bleeding.
Incline's patient-controlled analgesia system called IONSYS is for short-term management of acute post-operative pain.
More Articles on Anesthesia:
Anesthesia Machine Sales Expected to Pick Up in 2014
Heritage Valley Names Dr. Brett Anderson Chair of Anesthesiology
FDA Does Not Back Zogenix's Zohydro Pain Medication